Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives $3.2M Milestone from GSK Under Vaccine Collaboration

Premium

Alnylam Pharmaceuticals this week announced that it has received a $3.2 million milestone payment from GlaxoSmithKline related to the companies' collaboration on influenza vaccine production.

Late last year, Alnylam unveiled an initiative focused on applying its RNAi technology to the production of vaccines (GSN 11/3/2011). It also said that GlaxoSmithKline had signed on as its first partner under the effort.

This week, Alnylam said that the partnership is initially on influenza vaccine production in cell culture systems, and that GlaxoSmithKline is obligated to provide research funding and certain milestones. GlaxoSmithKline also has an option to apply the RNAi technology to two additional vaccine products.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.